Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium

Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. Rup, B.; Pallardy, M.; Sikkema, D.; Albert, T.; Allez, M.; Broet, P.; Carini, C.; Creeke, P.; Davidson, J.; De Vries, N.; Finco, D.; Fogdell-Hahn, A.; Havrdova, E.; Hincelin-Mery, A.; C Holland, M.; H Jensen, P. E.; Jury, E. C.; Kirby, H.; Kramer, D.; Lacroix-Desmazes, S.; Legrand, J.; Maggi, E.; Maillère, B.; Mariette, X.; Mauri, C.; Mikol, V.; Mulleman, D.; Oldenburg, J.; Paintaud, G.; R Pedersen, C.; Ruperto, N.; Seitz, R.; Spindeldreher, S.; Deisenhammer, F.; ABIRISK Consortium. Clinical and Experimental Immunology. 2015; 181: p.385-400. doi:10.1111/cei.12652
Article